Core - Pharmacology Laboratory Core

Jones, David R.

Abstract

The Pharmacology Core will provide a laboratory that will perform plasma and/or urine measurements of nucleoside analogs used in the treatment of HIV infection and antifungal agents used to treat opportunistic infections associated with AIDS. These measurements will be performed with the aid of analytical instruments and techniques, such as, high performance liquid chromatography, fluorescence polarization immunoassay, gas chromatography- mass spectrometry, and bioassays. The data from these measurements will be used to assess the pharmacokinetic disposition of the compounds which should aid the design of better therapeutic dosage regimens and the detection of possible drug interactions.
Our specific aims i nclude: 1. To describe inventory and storage procedures for samples. 2. To assess the pharmacokinetics of nucleoside analogs used in the treatment of HIV infection and anti-fungal agents used in the treatment of opportunistic infections associated with AIDS. 3. To describe the feasibility of assaying 500-1000 samples per year. 4. To describe our participation in quality assurance programs. 5. To show the capability of our laboratory to develop and implement new relevant analytical techniques.

Funding Agency

• Agency: National Institute of Health (NIH)
• Institute: National Institute of Allergy and Infectious Diseases (NIAID)
• Type: Research Project--Cooperative Agreements (U01)
• Project #: 5U01AI025859-08
• Application #: 3746773
• Support Year: 8
• Fiscal Year: 1994

Institution

• Name: Indiana University-Purdue University at Indianapolis
• DUNS #: 005436803
• City: Indianapolis
• State: IN
• Country: United States
• Zip Code: 46202

Publications

Martin, Maureen P; Naranbhai, Vivek; Shea, Patrick R et al. (2018) Killer cell immunoglobulin-like receptor 3DL1 variation modifies HLA-B*57 protection against HIV-1. J Clin Invest 128:1903-1912

Haas, David W; Bradford, Yuki; Verma, Anurag et al. (2018) Brain neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse events. Pharmacogenet Genomics 28:179-187

Venuto, Charles S; Lim, Jihoon; Messing, Susan et al. (2018) Inflammation investigated as a source of pharmacokinetic variability of atazanavir in AIDS Clinical Trials Group protocol A5224s. Antivir Ther 23:345-351

Li, Binglan; Verma, Shefali S; Veturi, Yogasudha C et al. (2018) Evaluation of PrediXcan for prioritizing GWAS associations and predicting gene expression. Pac Symp Biocomput 23:448-459

Gupta, Samir K; Yeh, Eunice; Kitch, Douglas W et al. (2017) Bone mineral density reductions after tenofovir disoproxil fumarate initiation and changes in phosphaturia: a secondary analysis of ACTG A5224s. J Antimicrob Chemother 72:2042-2048

Verma, Anurag; Bradford, Yuki; Verma, Shefali S et al. (2017) Multiphenotype association study of patients randomized to initiate antiretroviral regimens in AIDS Clinical Trials Group protocol A5202. Pharmacogenet Genomics 27:101-111

Bednasz, Cindy J; Venuto, Charles S; Ma, Qing et al. (2017) Efavirenz Therapeutic Range in HIV-1 Treatment-Naive Participants. Ther Drug Monit 39:596-603

Verma, Shefali S; Frase, Alex T; Verma, Anurag et al. (2016) PHENOME-WIDE INTERACTION STUDY (PheWIS) IN AIDS CLINICAL TRIALS GROUP DATA (ACTG). Pac Symp Biocomput 21:57-68

Moore, Carrie B; Verma, Anurag; Pendergrass, Sarah et al. (2015) Phenome-wide Association Study Relating Pretreatment Laboratory Parameters With Human Genetic Variants in AIDS Clinical Trials Group Protocols. Open Forum Infect Dis 2:ofu113

Lehmann, David S; Ribaudo, Heather J; Daar, Eric S et al. (2015) Genome-wide association study of virologic response with efavirenz-containing or abacavir-containing regimens in AIDS clinical trials group protocols. Pharmacogenet Genomics 25:51-9